Simulations Plus

Simulations Plus provides cutting-edge software solutions and consulting services designed to enhance drug discovery, clinical development, and regulatory submission processes. With over 25 years of experience, the company has established itself as a leader in translating scientific research into practical software applications. Their expertise encompasses ADMET property prediction, physiologically-based pharmacokinetics (PBPK) modeling, pharmacometrics, and quantitative systems pharmacology/toxicology (QST). Notable products include GastroPlus for simulating drug absorption and effects in humans and animals, ADMET Predictor for metabolism prediction and AI-driven drug design, and DILIsym for assessing drug-induced liver injury risks. The company also offers pharmacometrics analysis tools such as MonolixSuite, enabling efficient model-informed drug development. Furthermore, specialized software like NAFLDsym, OBESITYsym, and RENAsym provide mechanistic models for various medical conditions, enhancing treatment efficacy predictions. Simulations Plus supports professionals worldwide in improving healthcare outcomes through innovative modeling and simulation technologies.